

Shareholder approval VanEck Bionic Engineering UCITS ETF: Investment Objective and Policy Amendment

VanEck wishes to announce that the shareholders of the VanEck Bionic Engineering UCITS ETF (the “Fund”) approved the amendment of the investment objective and policy of the Fund at the Extraordinary General Meeting held on 14 August 2025.

The investment objective and policy of the Fund, as detailed in Section 1 of the Circular dated 21 July 2025, will be amended to reflect an adjustment to the index methodology to apply an additional screen for companies involved in the “medical robotics” industry when selecting the constituents of the index, which becomes effective on or around 19 September 2025 (the “Effective Date”).

As a result of the passing of the resolutions, to better align the name of the Fund with its revised investment objective and policy, the Fund will be re-named as of the Effective Date, as set out below:

Existing Fund name	Proposed Fund name
VanEck Bionic Engineering UCITS ETF	VanEck Medical Robotics and Bionic Engineering UCITS ETF

For further details on the current investment objective of the Fund, as well as the related amendments, please refer to following documentation published on www.vaneck.com:

- **Shareholder circular**
- **FAQ**

Yours faithfully,

VanEck UCITS ETFs plc

The representative in Switzerland is Zeidler Regulatory Services (Switzerland) AG, Neustadtgasse 1a, CH-8400 Winterthur (as of 1 September 2025: Stadthausstrasse 14, CH-8400 Winterthur), Switzerland. The prospectus, the articles of association, the Key Information Documents, the adjusted annual report and semiannual report as well as a list containing all purchases and sales which have been made during the reporting period can be obtained free of charge at the representative in Switzerland, Zeidler Regulatory Services (Switzerland) AG.

The paying agent in Switzerland is Helvetische Bank AG, Seefeldstrasse 215, CH-8008 Zurich, Switzerland.